Figure 2.

Nanobodies possess numerous advantageous characteristics, including their high antigen specificity (a) and high tumor targeting potential (b). a. ^99mTc-labeled-nanobody targeting the complement receptor of the Ig superfamily, CRIg, expressed on Kupffer cells in the liver. 3D-rendered SPECT/micro-CT images of naive wild-type (A.1.) and CRIg^−/− mice (A.2.) 1 h after intravenous injection of ^99mTc-labeled-nanobody. Representative images for 3 mice per group are shown. Figures adapted with permission from.[115] b. Dosimetry calculation of untagged ¹⁷⁷Lu-DTPA-anti-HER2 nanobody coinfused with 150 mg/kg Gelofusin, in HER2^pos tumor xenografted mice. Radiolabeling of nanobodies is characterized by significant retention of radioactivity at the kidneys, due to the charged-based aspecific tubular reuptake after glomerular filtration. Figure adapted with permission from.[109].